Related Experiment Video
Updated: Feb 18, 2026
07:52
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
20.5K
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
Xiaomin Niu1,2, Jody C Chuang3, Gerald J Berry4,5
1Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, People's Republic of China.
Current Treatment Options in Oncology
|November 17, 2017
Summary
Anaplastic Lymphoma Kinase (ALK) rearrangement testing is crucial for personalized lung cancer therapy. This review compares FISH, IHC, and NGS methods to guide optimal diagnostic choices for ALK-positive non-small cell lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Personalized targeted therapy is revolutionizing lung cancer treatment.
- Anaplastic Lymphoma Kinase (ALK) rearrangements drive a subset of non-small cell lung cancers (NSCLCs).
- ALK-targeted therapies show high response rates in ALK-positive NSCLC patients.
Purpose of the Study:
- To review current methods for detecting ALK rearrangements in NSCLC.
- To discuss the advantages and disadvantages of available ALK detection techniques.
- To inform the choice of diagnostic methodology for ALK rearrangement detection.
Main Methods:
- Fluorescent in situ hybridization (FISH)
- Immunohistochemistry (IHC)
- Polymerase Chain Reaction (PCR)-based Next Generation Sequencing (NGS)
Main Results:
- FISH, IHC, and NGS are the primary methods for ALK rearrangement detection.
- Each method possesses distinct advantages and limitations.
- The optimal diagnostic strategy may involve combining multiple testing methods.
Conclusions:
- Accurate and reproducible ALK rearrangement detection is vital for patient selection.
- The choice of diagnostic method for ALK testing remains a subject of clinical debate.
- Combining detection methods may enhance diagnostic accuracy for ALK fusions in NSCLC.
